Core Insights - Arvinas, Inc. is set to present data from its first-in-human study of ARV-102, a drug targeting LRRK2, at the International Conference on Alzheimer's and Parkinson's Diseases in April 2025 [1][3] - ARV-102 is designed as a PROTAC to degrade LRRK2, which is linked to Parkinson's disease and progressive supranuclear palsy [2][4] - The presentation will focus on the safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy males [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies for serious diseases using its PROTAC platform [5] - The company is advancing multiple investigational drugs, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5] - Arvinas is headquartered in New Haven, Connecticut, and aims to improve patient outcomes through innovative protein degradation therapies [5]

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical- stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria. ARV-102 is Arvinas' investig ...

Core Viewpoint - Arvinas, Inc. (ARVN) has experienced significant selling pressure, resulting in a 54.9% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating a potential turnaround for the company [1]. Group 1: Stock Performance and Technical Indicators - The stock is currently in oversold territory, with a Relative Strength Index (RSI) reading of 23.18, suggesting that the heavy selling may be exhausting itself and a price reversal could be imminent [5][6]. - A stock is generally considered oversold when its RSI falls below 30, indicating a potential entry opportunity for investors [2][3]. Group 2: Earnings Estimates and Analyst Sentiment - Over the last 30 days, the consensus earnings per share (EPS) estimate for ARVN has increased by 1.2%, reflecting a strong agreement among analysts to raise earnings estimates for the current year [6]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Viewpoint - Arvinas, Inc. (ARVN) has experienced significant selling pressure, resulting in a 54% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential rebound [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for ARVN is currently at 24.51, indicating that the stock is in oversold territory, which may suggest an imminent trend reversal [5]. - RSI is a momentum oscillator that helps identify whether a stock is overbought or oversold, with a reading below 30 typically indicating oversold conditions [2][3]. Group 2: Fundamental Indicators - There has been a consensus among sell-side analysts to raise earnings estimates for ARVN, leading to a 1.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Company Overview - Arvinas, Inc. (ARVN) shares increased by 8.8% to close at $9.03, following a trading session with significantly higher volume than usual, despite a 53.1% loss over the past four weeks [1] - The stock's recovery came after mixed results from a late-stage breast cancer study of vepdegestrant, which is in phase III VERITAC-2 study for advanced or metastatic breast cancer [2] Financial Performance - The company is projected to report a quarterly loss of $0.85 per share, reflecting a year-over-year increase of 12.4%, with expected revenues of $58.14 million, marking a 129.8% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 26.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Arvinas is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Certara, Inc. (CERT), saw a 1% increase to $11.01 but has a -21.4% return over the past month [4] - Certara's consensus EPS estimate has decreased by 23.8% to $0.10, showing no change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [5]

Core Insights - Arvinas, Inc. and Pfizer Inc. announced topline results from the Phase 3 VERITAC-2 trial for vepdegestrant in advanced or metastatic breast cancer patients [1][2] - The trial focused on estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) patients who had disease progression after prior treatments [2] Trial Results - The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, showing a statistically significant improvement in progression-free survival (PFS) compared to fulvestrant [3] - The results surpassed the pre-specified target hazard ratio of 0.60 in the ESR1m population [4] - No statistical significance was found in PFS improvement in the intent-to-treat (ITT) population, and overall survival data was not mature at the time of analysis [4] Future Plans and Designations - The trial will continue to evaluate overall survival as a key secondary endpoint [5] - Vepdegestrant was generally well tolerated during the trial [5] - Detailed results will be presented at a medical meeting later this year, and the FDA granted Fast Track designation for vepdegestrant for monotherapy in eligible patients [5] Market Reaction - Following the trial results, ARVN stock experienced a decline of 52.4%, trading at $8.35 [6]

Core Insights - The Phase 3 VERITAC-2 clinical trial demonstrated that vepdegestrant significantly improved progression-free survival (PFS) in the estrogen receptor 1-mutant (ESR1m) population compared to fulvestrant, achieving a hazard ratio of 0.60 [1][2] - Vepdegestrant is the first PROTAC degrader to show clinical benefit in a Phase 3 trial, indicating its potential as a first-in-class treatment for advanced or metastatic breast cancer [1][3] Company Overview - Arvinas, Inc. and Pfizer Inc. are jointly developing vepdegestrant, an investigational oral PROTAC ER degrader targeting ER+/HER2- breast cancer [4][10] - The FDA granted Fast Track designation for vepdegestrant, facilitating its development for patients previously treated with endocrine therapy [4][10] Clinical Trial Details - The VERITAC-2 trial enrolled 624 patients across 26 countries, focusing on those with ER+/HER2- advanced or metastatic breast cancer who had previously received CDK4/6 inhibitors and endocrine therapy [7][8] - The primary endpoint was PFS, with overall survival being a key secondary endpoint that will continue to be assessed [3][8] Patient Population and Disease Context - Approximately 2.3 million new breast cancer cases were reported globally in 2022, with ER+/HER2- breast cancer accounting for about 70% of all cases [5] - Nearly 30% of women diagnosed with early-stage breast cancer may develop metastatic breast cancer, with ESR1 mutations found in approximately 40% of patients in the second-line setting [6]

Core Viewpoint - Arvinas, Inc. (ARVN) shows significant upside potential with a mean price target of $58.21, indicating a 228.9% increase from the current price of $17.70 [1] Price Targets - The average comprises 19 short-term price targets ranging from a low of $30 to a high of $82, with a standard deviation of $14.24, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 69.5% increase, while the most optimistic estimate points to a 363.3% upside [2] - A tight clustering of price targets, represented by a low standard deviation, indicates high agreement among analysts about the stock's price movement direction [7] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][9] - The Zacks Consensus Estimate for the current year has increased by 18.1% over the past month, with 10 estimates going higher and one going lower [10] - ARVN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research shows that they often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Core Viewpoint - Arvinas, Inc. (ARVN) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Recent Performance and Outlook - Arvinas is projected to earn -$3.87 per share for the fiscal year ending December 2025, representing a year-over-year decline of 39.7% [8]. - Over the past three months, the Zacks Consensus Estimate for Arvinas has increased by 11.8%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of Arvinas to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Arvinas, Inc. (ARVN) shows potential for significant upside, with a mean price target of $59.21 indicating a 235.1% increase from the current price of $17.67, based on Wall Street analysts' short-term estimates [1][2]. Price Targets and Estimates - The mean estimate consists of 19 short-term price targets, with a standard deviation of $15.62, indicating variability among analysts [2]. - The lowest price target of $30 suggests a 69.8% increase, while the highest target of $88 implies a potential surge of 398% [2]. - Analysts' price targets can be misleading, as empirical research shows they often do not accurately predict stock price movements [5][6]. Earnings Estimates - Analysts are optimistic about ARVN's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][9]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 12.5%, with eight estimates moving higher and one lower [10]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]. Analyst Agreement - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [7]. - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research into fundamental drivers [8][12].